Gastroparesis Drugs Market Expansion Is Opening New Pathways For Strategic Investment
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Gastroparesis Drugs Market Forecast Highlighting Growth From $6.02 Billion To $7.36 Billion
The gastroparesis drugs market has experienced robust expansion over recent years. Projections indicate a rise from $5.7 billion in 2025 to $6.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historical growth has been driven by factors such as a higher number of diabetic gastroparesis diagnoses, the prolonged use of prokinetic and antiemetic agents, an increase in gastrointestinal disorders linked to diabetes, the availability of both over-the-counter and prescription symptom management options, and a broader reach of gastroenterology healthcare services.
The market for gastroparesis medications is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $7.37 billion, reflecting a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period is driven by several key factors: the increasing global incidence of diabetes, a heightened recognition of gastroparesis as a persistent medical issue, a growing need for reliable solutions that deliver sustained symptom relief, enhanced availability of specialized gastrointestinal healthcare services, and the persistent demand for more effective therapies that improve gastric motility. Among the notable developments shaping this forecast period are a stronger dependence on prokinetic drugs to manage symptoms, a higher adoption of combined drug regimens specifically for gastroparesis, an increase in treatments requiring a prescription, the evolution of therapeutic strategies focused more directly on symptom alleviation, and the wider use of oral medications intended for extended care management.
Download A Free Sample Report For Comprehensive Market Insights:
Gastroparesis Drugs Market Expansion Supported By Key Demand Factors
The rising incidence of diabetes is anticipated to drive expansion in the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition marked by high blood glucose levels due to insufficient insulin production or ineffective insulin use. Its prevalence is climbing because of sedentary lifestyles, poor dietary habits, genetic factors, urbanization, aging populations, and increasing obesity rates. The gastroparesis drugs market aids diabetes management by offering medications that alleviate symptoms like nausea, vomiting, and delayed gastric emptying—common gastrointestinal issues linked to diabetic gastroparesis. For example, in March 2024, the Office for Health Improvement & Disparities, a UK government agency, reported that from March 2022 to March 2023, the number of type 1 diabetes patients receiving all eight recommended care processes grew by 22%, type 2 diabetes patients saw a 21% rise, and the proportion achieving target HbA1c levels reached 37.9%, the highest ever recorded by the National Diabetes Audit. Consequently, the growing prevalence of diabetes is fueling the gastroparesis drugs market’s growth.
Gastroparesis Drugs Market Categorization By Product Type And Application
The gastroparesis drugs market covered in this report is segmented –
1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce
Subsegments:
1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants
Gastroparesis Drugs Market Growth Trends Influencing Competitive Dynamics
Key players in the gastroparesis drugs market are actively developing advanced treatments, including novel prokinetic therapies aimed at improving gastric motility and alleviating symptoms. These therapies, which are newly formulated medications, work by stimulating and enhancing the natural movement of the stomach and intestines to facilitate more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a biopharmaceutical company based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of its New Drug Application (NDA) for tradipitant to address gastroparesis symptoms. This approval specifically pertains to tradipitant, an investigational oral neurokinin-1 receptor antagonist designed to treat gastroparesis, a severe digestive disorder for which existing treatment options are limited. This acceptance represents a crucial regulatory achievement for Vanda as it moves forward in seeking marketing authorization for tradipitant among patients suffering from gastroparesis.
Gastroparesis Drugs Market Company Landscape And Strategic Competition
Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.
Access The Complete Gastroparesis Drugs Market Report:
Gastroparesis Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
